ValueQ4, 24Q4, 25TTMSelling/general/admin expenses———Research & development———Operating income———Non-Operating Income, Total———Interest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses———Unusual income/expense———Pretax income———Equity in earnings———Taxes———Non-controlling/minority interest———After tax other income/expense———Net income before discontinued operations———Discontinued operations———Net income———Dilution adjustment———Preferred dividends———Diluted net income available to common stockholders———Basic earnings per share (Basic EPS)———Diluted earnings per share (Diluted EPS)———Average basic shares outstanding———Diluted shares outstanding———EBITDA———EBIT———Cost of revenue———Other cost of goods sold———Depreciation & amortization (cash flow)———
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.